Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» myasthenia gravis
myasthenia gravis
Roche autoimmune disease drug disappoints in closely watched trial
BioPharma Dive
Thu, 03/21/24 - 06:36 pm
Roche
Chugai
clinical trials
myasthenia gravis
Enspryng
J&J’s growing rare disease focus brings a potential multi-use treatment to the table
Pharma Voice
Thu, 03/7/24 - 05:29 pm
JNJ
nipocalimab
myasthenia gravis
J&J's immune disorder drug succeeds in mid and late-stage studies
Reuters
Mon, 02/5/24 - 10:14 am
JNJ
autoimmune disease
clinical trials
nipocalimab
myasthenia gravis
Sjögren’s syndrome
Argenx's Vyvgart gains commercial momentum in gMG as company plots expansion into new uses
Fierce Pharma
Wed, 11/1/23 - 11:04 am
Argenx
Vygart
myasthenia gravis
FDA Approves UCB’s Complement Inhibitor for Generalized Myasthenia Gravis
BioSpace
Wed, 10/18/23 - 11:22 am
UCB Pharma
Zilbrysq
myasthenia gravis
UCB stakes claim to gMG market as FDA clears Rystiggo
Pharmaphorum
Tue, 06/27/23 - 11:21 am
UCB Pharma
Rystiggo
myasthenia gravis
FDA
Sanofi Admits Defeat for Myasthenia Gravis Candidate, Drops Phase III Trial
BioSpace
Fri, 02/3/23 - 10:31 am
Sanofi
tolebrutinib
myasthenia gravis
Argenx Scores Priority Review for Generalized Myasthenia Gravis Therapeutic
BioSpace
Tue, 11/22/22 - 04:30 pm
Argenx
FDA
priority reviews
myasthenia gravis
efgartigimod
Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod
Fierce Pharma
Tue, 09/27/22 - 10:16 am
Argenx
Vyvgart
myasthenia gravis
efgartigimod
FDA
As Vyvgart launch gains steam, Argenx CEO says his company can achieve 'standalone' success
Fierce Pharma
Wed, 09/14/22 - 09:41 am
Argenx
Vyvgart
innovation
myasthenia gravis
FDA Partially Halts Sanofi’s BTK Inhibitor for Multiple Sclerosis, Myasthenia Gravis
Pharma Live
Thu, 06/30/22 - 10:59 am
Sanofi
multiple sclerosis
myasthenia gravis
FDA
tolebrutinib
clinical trials
clinical hold
Janssen Recruiting for Phase III Trials of Potential Myasthenia Gravis Game Changer
BioSpace
Mon, 06/20/22 - 10:57 am
Janssen
JNJ
clinical trials
nipocalimab
myasthenia gravis
AstraZeneca's Ultomiris scores its 3rd FDA approval, setting up market clash with argenx
Fierce Pharma
Thu, 04/28/22 - 11:05 am
AstraZeneca
Ultomiris
FDA
myasthenia gravis
Argenx takes a step towards convenience
EP Vantage
Wed, 03/23/22 - 10:27 am
Argenx
efgartigimod
Vyvgart
myasthenia gravis
Argenx's Vygart launch finds quick neurologist support over AstraZeneca's well-entrenched Soliris for myasthenia gravis
Fierce Pharma
Thu, 02/17/22 - 11:13 pm
Argenx
Vygart
myasthenia gravis
neurologists
Watch out, AstraZeneca: UCB uncorks late-stage success for $2.1B Soliris rival
Endpoints
Fri, 02/4/22 - 11:11 am
UCB Pharma
clinical trials
myasthenia gravis
AstraZeneca
Soliris
zilucoplan
UCB chases after Argenx with FcRN drug for myasthenia gravis
Pharmaforum
Mon, 12/13/21 - 10:48 am
UCB Pharma
anti-FcRn
myasthenia gravis
rozanolixizumab
Go or no go? Argenx's December showdown
EP Vantage
Wed, 12/1/21 - 10:10 am
FDA
Argenx
efgartigimod
myasthenia gravis
Calliditas
Nefcon
Merck
Keytruda
AstraZeneca's newly acquired Soliris is overpriced in myasthenia gravis, cost watchdog says
Fierce Pharma
Sun, 07/25/21 - 11:44 am
AstraZeneca
Soliris
Alexion
drug pricing
myasthenia gravis
Alexion touts new PhIII data of Soliris successor as planned AstraZeneca takeover looms
Endpoints
Fri, 07/16/21 - 10:40 am
Alexion
AstraZeneca
M&A
clinical trials
Ultomiris
myasthenia gravis
Pages
1
2
next ›
last »